Welcome to our dedicated page for CONCENTRA GROUP HOLDINGS PAREN news (Ticker: CON), a resource for investors and traders seeking the latest updates and insights on CONCENTRA GROUP HOLDINGS PAREN stock.
Concentra Group Holdings Parent, Inc. reports developments tied to its U.S. occupational health services business, including financial results, guidance, cash dividends, and operating updates. The company serves employers and workers through occupational health centers, onsite health clinics, direct-to-employer care, and Concentra Telemed.
Recurring news themes include medical center openings in regional markets, work injury care, physical therapy, drug testing, DOT physical exams, pre-placement exams, and telemedicine for minor work injuries. Company updates also cover leadership transitions, annual and quarterly reporting schedules, balance sheet commentary, and the expansion of Concentra's national occupational medicine network.
Concentra (NYSE: CON) reported Q2 2026 revenue of $606.0 million, up 10.0% year over year, with net income of $67.3 million, up 45.7%. Net income attributable to the company was $65.3 million and Adjusted EBITDA was $140.9 million, up 22.5%. EPS was $0.51 and Adjusted EPS $0.52.
The company generated $135.2 million in operating cash flow and $121.0 million in Free Cash Flow, while capital expenditures fell to $15.7 million. Total debt was $1,573.6 million with cash of $158.0 million and a net leverage ratio of 2.99x. The board declared a $0.0625 per-share cash dividend and the company repurchased 0.4 million shares for $11.0 million.
Concentra raised its 2026 guidance, now expecting revenue of $2.325–$2.375 billion, Adjusted EBITDA of $485–$495 million, Free Cash Flow of $220–$240 million, capex of $70–$80 million and net leverage below 3.0x. Effective November 1, 2026, president and CFO Matt DiCanio will become president and CEO, while current CEO Keith Newton will transition to executive chairman.
Concentra (NYSE: CON) announced the opening of its first Idaho medical center in Federal Way Plaza at 3237 South Federal Way, near Boise Airport, with a ribbon-cutting on July 22. The Boise site expands access to occupational and workforce health services for employers and employees across the Treasure Valley.
The center offers work injury care, physical therapy, drug testing, DOT and pre-placement exams, medical surveillance, and workforce health programs, plus telemedicine via Concentra Telemed. According to Concentra, this move extends its nationwide network of 632 centers and 411 onsite clinics that support about 54,000 patients each business day.
Concentra (NYSE: CON) announced the opening of a new occupational health medical center near Kansas City International Airport, located at 10304 NW Prairie View Road, Kansas City, Missouri 64153. The facility, called Concentra Kansas City Airport, expands the company’s presence in Missouri and aims to support the region’s growing business and transportation hub.
The center offers work injury care, physical therapy, drug and alcohol testing, Department of Transportation physicals, pre-placement exams, medical surveillance, and other occupational health services. According to Concentra, employees with minor work-related injuries can also access care through Concentra Telemed, its proprietary telemedicine platform, enhancing convenience and continuity of workforce health services.
Concentra (NYSE: CON) will release its second quarter 2026 financial results, for the period ended June 30, 2026, on Thursday, August 6, 2026, after the market close.
The company will host a live webcast conference call on Friday, August 7, 2026, at 9 a.m. Eastern Time.
Concentra (NYSE:CON) opened a new medical center in Goodyear, Arizona, bringing its Arizona footprint to 17 locations. The center, located at 2403 North Pebble Creek Parkway, Suite 101, expands access to occupational health services for employers and employees in the growing West Valley industrial area.
The facility offers work injury care, physical therapy, drug testing, DOT physicals, pre-placement exams, medical surveillance programs, and digital injury management through Concentra HUB.
Concentra (NYSE: CON) reported Q1 2026 results and raised full-year guidance on May 7, 2026. Q1 revenue was $569.6M (+13.7% YoY), net income $52.3M (+28.7% YoY), Adjusted EBITDA $120.7M (+17.6% YoY), and patient visits totaled 3.42M (+6.7% YoY). The board declared a cash dividend of $0.0625 per share. Full-year 2026 guidance: revenue $2.275–2.375B, Adjusted EBITDA $460–480M, net leverage 3.0x, and Free Cash Flow $215–235M.
Concentra (NYSE: CON) announced that Dr. John Anderson, executive vice president and Chief Medical Officer, will retire at the end of 2026 after 33 years with the company. The company has begun a formal search for his successor and said Anderson will provide advisory support via a consulting arrangement.
Dr. Anderson served as CMO since 2014 and joined Concentra in 1993. Concentra reported about 13,000 colleagues, serving ~53,000 patients per business day across 628 centers and 411 onsite clinics as of December 31, 2025.
Concentra (NYSE: CON) will release first quarter 2026 results for the period ended March 31, 2026, on Thursday, May 7, 2026 after market close. The company will host a live conference call and webcast on Friday, May 8, 2026 at 9:00 a.m. ET.
Investors can access the live webcast via the company website and replay will be available afterward. Concentra supports care at 628 occupational centers, 411 onsite clinics and Concentra Telemed, serving about 53,000 patients per business day, with roughly 13,000 colleagues and affiliated clinicians (as of Dec 31, 2025).
Concentra (NYSE: CON) reported strong Q4 2025 and full‑year results: Q4 revenue $539.1M (+15.9%), Q4 net income $36.2M (+58.7%), and Q4 Adjusted EBITDA $95.3M (+22.9%). For FY2025, revenue was $2.163B (+13.9%), Adjusted EBITDA $431.9M (+14.6%), and Free Cash Flow $197.8M.
The company ended 2025 with 628 occupational centers, 411 onsite clinics, cash of $79.9M, total debt of $1,574.4M, and net leverage ~3.4x. 2026 guidance: revenue $2.25–2.35B; Adjusted EBITDA $450–470M; Free Cash Flow $200–225M.
Concentra (NYSE: CON) reported preliminary unaudited results for Q4 and FY2025 and provided full‑year 2026 guidance. Key 2025 metrics: FY revenue $2,163.4M (+13.9%), Adjusted EBITDA $431.9M (+14.6%), free cash flow $197.8M, capital expenditures $82.3M (+28%), and net leverage ~3.4x. Q4 revenue was $539.1M and Adj EBITDA $95.3M. For 2026 the company expects revenue $2.25–2.35B, Adjusted EBITDA $450–470M, free cash flow $200–225M, and target net leverage ≤3.0x. Full results will be released Feb 26, 2026 with a conference call Feb 27, 2026.